4DMT Grants 67,600 RSUs to 5 New Employees

Biotech firm awards stock units to recruit new talent under Nasdaq-approved inducement plan.

Apr. 17, 2026 at 8:05pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of legal documents, a pen, and a pair of reading glasses arranged elegantly on a clean, white seamless background, conceptually representing the corporate strategy and legal processes behind 4DMT's employee equity grants.4DMT's strategic use of employee equity grants to recruit top talent reflects the company's ambitious growth plans as it advances its pipeline of innovative therapeutics.Emeryville Today

4D Molecular Therapeutics (4DMT), a late-stage biotechnology company, announced that it has granted 67,600 Restricted Stock Units (RSUs) to five new non-executive employees. The RSUs were awarded on April 14, 2026, under the company's 2025 Employment Inducement Award Plan, a Nasdaq-allowed program used to recruit new talent outside of 4DMT's regular equity plan.

Why it matters

The RSU grants are part of 4DMT's strategy to attract top talent as it advances its pipeline of durable and disease-targeted therapeutics, including lead candidates 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis. Recruiting and retaining skilled employees is crucial for 4DMT as it works to transform treatment paradigms and provide unprecedented benefits to patients.

The details

The 67,600 RSUs were granted to five new non-executive employees of 4DMT on April 14, 2026. The awards were approved by the company's compensation committee and granted under 4DMT's 2025 Employment Inducement Award Plan, a Nasdaq-allowed program used to recruit new employees outside of the firm's regular equity plan.

  • The RSU grants were approved by 4DMT's compensation committee on April 14, 2026.

The players

4D Molecular Therapeutics (4DMT)

A leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients.

Got photos? Submit your photos here. ›

The takeaway

4DMT's use of its Nasdaq-approved inducement plan to grant RSUs to new employees highlights the company's commitment to recruiting top talent as it advances its pipeline of innovative therapies. This strategy is crucial for 4DMT as it works to bring transformative treatments to patients in need.